SAGE vs. NUVB, WVE, NRIX, PAHC, COGT, AUPH, PRTC, CVAC, ANAB, and GHRS
Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Nuvation Bio (NUVB), Wave Life Sciences (WVE), Nurix Therapeutics (NRIX), Phibro Animal Health (PAHC), Cogent Biosciences (COGT), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), CureVac (CVAC), AnaptysBio (ANAB), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Nuvation Bio (NYSE:NUVB) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.
Nuvation Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -552.52%. Sage Therapeutics' return on equity of -11.31% beat Nuvation Bio's return on equity.
Sage Therapeutics received 595 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 72.09% of users gave Nuvation Bio an outperform vote while only 67.82% of users gave Sage Therapeutics an outperform vote.
Nuvation Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 36.1% of Nuvation Bio shares are held by insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Nuvation Bio currently has a consensus target price of $6.60, indicating a potential upside of 93.55%. Sage Therapeutics has a consensus target price of $37.67, indicating a potential upside of 213.63%. Given Nuvation Bio's higher possible upside, analysts plainly believe Sage Therapeutics is more favorable than Nuvation Bio.
Nuvation Bio has higher earnings, but lower revenue than Sage Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvation Bio had 6 more articles in the media than Sage Therapeutics. MarketBeat recorded 9 mentions for Nuvation Bio and 3 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 0.93 beat Nuvation Bio's score of 0.24 indicating that Nuvation Bio is being referred to more favorably in the media.
Summary
Nuvation Bio beats Sage Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Sage Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sage Therapeutics Competitors List
Related Companies and Tools
